Drug Trial Radar · NCT02631070
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Last checked: Nov 20, 2026Latest source record: Dec 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
229
Actual
Start
Feb 9, 2016
Primary completion
Jun 18, 2019
Study completion Nov 26, 2020
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- First posted
- Dec 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in participants with anemia due to the Revised International Prognostic Scoring System (IPSS-R) very low, low, or intermediate MDS with ring sideroblasts who require red blood cell (RBC) transfusions.
Conditions
- Myelodysplastic Syndromes
Interventions
LuspaterceptDrug
PlaceboOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 Weeks From Week 1 to Week 24Time frame: From Week 1 through Week 24 of study treatment
Locations
74 sites in 11 countries. Site status is shown where the registry gives one.
Stanford Cancer Center
Stanford, California
Yale University School of Medicine
New Haven, Connecticut
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Emory University Hospital
Atlanta, Georgia
Ochsner Medical Institutions
New Orleans, Louisiana
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Karmanos Cancer Institute
Detroit, Michigan
Columbia-Presbyterian Medical Center
New York, New York
Montefiore Medical Center Albert Einstein Cancer Center
The Bronx, New York
Gabrail Cancer Center
Canton, Ohio
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Algemeen Ziekenhuis Klina
Brasschaat, Belgium
AZ Sint-Jan AV Brugge
Bruges, Belgium
UZ Brussels
Brussels, Belgium
Grand Hopital de Charleroi
Charleroi, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Cliniques Universitaires UCL de Mont-Godine
Yvoir, Belgium
Tom Baker Cancer Center
Calgary, Alberta, Canada
Juravinski Cancer Centre
Hamilton, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
CHU d'Angers
Angers, France
CHU Hotel
Grenoble, France
CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang
Lille, France
Institut Paoli Calmettes
Marseille, France
CHU de Nice Archet I
Nice, France
Hopital Saint Louis
Paris, France
Hopital Haut Leveque
Pessac, France
Centre hospitalier Lyon Sud Hematologie
Pierre-Bénite, France
Hopital civil
Strasbourg, France
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
Hopital Bretonneau
Tours, France
Universitatsklinikum Bonn
Bonn, Germany
Universitatsklinikum Carl Gustav Carus an der TU Dresden
Dresden, Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Marien Hospital
Düsseldorf, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.